Type 2 Diabetes

March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.

The FDA has approved insulin icodec-abae as the first once-weekly basal insulin option for glycemic control in adults with type 2 diabetes.

On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...

Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.

The FDA has approved empagliflozin, and empagliflozin and hydrochloride to help manage type 2 diabetes in pediatric patients.